CD31 gene polymorphisms are implicated in the pathogenesis of graft-versus-host disease (GvHD) following haematopoietic stem cell transplantation (HST). We investigated the influence of CD31 genotype on the incidence of GvHD following HST from an human leukocyte antigen (HLA)-identical sibling donor. Donor and recipient CD31 codons 125, 563 and 670 DNA polymorphisms were determined in 85 cases of HLA identical sibling HST from two transplant centres. A correlation between CD31 genotype and acute GvHD was considered significant if observed in patients from both transplant centres independently. A strong correlation was identified between donor CD31 codon 125 genotype and the incidence of acute GvHD. Acute GvHD grades II-IV occurred in 27 of 46 (59%) recipients with a CD31 codon 125 leucine/valine heterozygous donor compared to nine of 39 (23%) recipients with a CD31 codon 125 homozygous donor (P ¼ 0.0019, relative-risk 2.45, 95% confidence interval 1.3-4.5). This correlation was significant in patients from both transplant centres (P ¼ 0.015 and P ¼ 0.019). We suggest that CD31 genotype may influence the function of donor-derived leukocytes and may be informative when there is a choice of comparable donors. Bone Marrow Transplantation (2005) 36, 151-156.
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Haematopoietic stem cell transplantation (HST) using a human leucocyte antigen (HLA) identical allogeneic donor is the treatment of choice for certain categories of patients with haematological disorders. The best source of allogeneic haematopoietic stem cell donor is an HLA-identical sibling in which familial inheritance of HLA haplotypes ensures a complete match. Despite a complete allelic HLA match, graft-versus-host disease (GvHD) still occurs in up to 50% of transplants using an HLA identical sibling donor. The occurrence of GvHD on the background of HLA identity is likely to be due to differences at minor histocompatibility loci. 1 Behar et al 2 suggested that CD31 codon 125 (CD31-125) gene polymorphisms influence the incidence of GvHD by acting as a minor histocompatibility antigen (mHAg), although this was not supported by others. 3, 4 Furthermore, Maruya et al 5 , Grumet et al 6 and Balduini et al 7 identified an association between acute GvHD and compatibility for CD31 codons 563 and 670 (CD31-563 and CD31-670), suggesting that they are immunodominant mHAg. More recently, however, CD31 has been recognised as having a central role in the activation of lymphocytes following recognition of alloantigen and to coordinate leucocyte adhesion and extravasation. 8 CD31 polymorphism may, therefore, effect functional activity of cells that initiate GvHD.
The influence of genetic polymorphisms on the outcome of HST has been the subject of many studies but discordant findings have produced little consensus. 9 This may be a result of overall weak influence of nonMHC polymorphisms on a complex and multifactorial disease or, in some cases, due to multiple observations and chance findings in small patient cohorts. 10 In this study, we have investigated the effect of CD31 gene polymorphisms on the incidence of acute GvHD in HLA identical sibling donor HST in independent patient cohorts obtained from two transplant centres. We considered a correlation to be significant only if it was observed in the whole study cohort and in both individual centres separately. This study design reduces the likelihood of a statistical correlation being due to chance alone.
Patients and methods
The patients identified for this study were from two bone marrow transplant centres, who engrafted following HST from an HLA identical sibling donor. The study cohort consisted of 85 cases (Cambridge N ¼ 57, Manchester N ¼ 28) where archived DNA samples from both donor and recipient pairs were available and there was complete clinical follow-up data for 1-year post transplantation or until patient death. Of the 85 patients, 83 (98%) were white Northern European Caucasians. Informed consent to use tissue for research (including genetic research) was obtained from all donors and recipients at the time of transplant work-up. Patient age, gender, diagnosis, source of stem cells and post transplant immunosuppressive protocols are shown in Table 1 .
Genomic DNA obtained from archived pre-transplant peripheral blood samples (stored at À201C) was prepared using standard techniques. DNA typing for CD31-125 gene polymorphism was performed by PCR using sequence specific primers as described by Behar et al. 2 DNA typing for CD31-563 gene polymorphisms were identified as above using a common forward 5 0 primer Cgg Tgg ATg Agg TCC AgA TT and reverse 3 0 primers CTC TCC CTC CTg TTC CTT gT (amplifying CD31 codon-563 asparagine (CD31-563N)) or TCT CCC TCC TgT TCC TTg C (amplifying CD31 codon-563 serine (CD31-563S)). DNA typing for CD31-670 gene polymorphisms were identified using a forward 5 0 primer Agg TCA CAA TgA CgA TgT CA (amplifying CD31 codon-670 arginine (CD31-670R)) or forward 5 0 primer ggT CAC AAT gAC gAT gTC g (amplifying CD31 codon-670 glycine (CD31-670G)) and a common reverse 3 0 primer TAC CTT CAT TgA CAC ATC gg.
Transplant outcome data collected from patient medical records were assimilated with test results and anonymised in accordance with local research ethics committee guidelines. Univariate analysis was performed between donor and recipient gene polymorphism test results and the incidence and severity of acute GvHD and 1-year patient survival. The Fisher exact test was used where subgroups contained less than five cases. A correlation was only considered to be significant if it was observed in the combined study cohort (Yates corrected Po0.01) and in both transplant centres individually (Yates corrected Po0.05).
Results

Clinical outcome and transplant centre
There were no differences between recipient and donor demographics, incidence of acute or chronic GvHD or 1 year patient survival between the two transplant centres (Table 1) . Of the 85 patients studied, 38 (44.7%) had no acute GvHD, 11 (12.9%) had acute GvHD grade I, 18 (21.2%) had acute GvHD grade II, 11 (12.9%) had acute GvHD grade III and seven (8.2%) had acute GvHD grade IV. Of the 57 patients transplanted in Cambridge 24 (42%) had acute GvHD grades II-IV and 12 of 28 (43%) patients transplanted in Manchester had acute GvHD grades II-IV. 
CD31 gene polymorphism and GvHD
CD31 alleles encode either leucine or valine at codon 125, asparagine (N) or serine (S) at codon 563, and arginine (R) or glycine (G) at codon 670. There was complete linkage between CD31-563N and CD31-670G genotypes, and between CD31-563S and CD31-670R genotypes. We, therefore, refer to CD31-563 and CD31-670 genotypes together as CD31-563/670. There was also strong, but not complete linkage between CD31 codon-125 valine (CD31-125V) and CD31-563N/670G, and between CD31 codon-125 leucine (CD31-125L) and CD31-563S/ 670R (Po0.0001).
We considered a potential role of CD31 gene polymorphism acting as a mHAg (donor and recipient compatibility in the GvH direction) and also a possible functional effect on donor and/or recipient lymphocytes. CD31-125 donor and recipient compatibility (ie functioning as a mHAg) was weakly correlated with the incidence and severity of acute GvHD (P ¼ 0.059), although this was not significant in patients from both centres ( Table 2 ). There was no correlation observed between donor and recipient CD31-563/670 compatibility and acute GvHD (data not shown).
We then considered a possible functional effect of recipient and/or donor CD31 genotype. Data was first analysed by recipient and donor CD31 genotype: CD31-125L, À125V and À125LV, and CD31-563N/670G, À563S/ 670R and À563NS/670GR. We observed no differences in the incidence of acute GvHD grades II-IV related to recipient CD31 genotype (data not shown). In contrast, donor CD31-125 genotype correlated strongly with acute GvHD (combined study cohort P ¼ 0.003, Cambridge P ¼ 0.028 and Manchester P ¼ 0.032). The incidence of acute GvHD did not differ between CD31-125L and CD31-125V homozygous donors and both of these differed from the CD31 codon-125 leucine and valine (CD31-125LV) heterozygous donors. Of 46 patients transplanted with donor stem cells that were heterozygous for CD31-125LV 27 (59%) had acute GvHD grades II-IV compared to only nine of 39 (23%) patients transplanted with donor stem cells that were homozygous at this loci (Table 3a , P ¼ 0.0019, relative risk 2.45, 95% confidence intervals 1.3-4.5).
The correlation between donor CD31-125 genotype and the incidence of acute GvHD grades II-IV were significant for patients transplanted in both centres independently (Table 3a) . For recipients of allogeneic stem cells obtained from a CD31-125LV heterozygous donor, 17 of 30 (57%) 
)).
Time-to-event analysis using the log-rank test censored by patient death or relapse strongly support the finding that donor CD31-125 genotype is associated with acute GvHD (Figure 1) . Donor CD31-563/670 genotype also correlated with the incidence of acute GvHD grades II-IV (Table 3b , P ¼ 0.048). Of 22 patients with donor CD31-563S/670R 13 (59%) had acute GvHD compared to only four of 19 patients (21%) with donor CD31-563N/670G. This difference was not, however, significant in patients from both centres independently (Cambridge P ¼ 0.26, Manchester P ¼ 0.005). When donor CD31-125 and CD31-563/670 genotype were considered together, there was also a strong correlation (Table 4 , P ¼ 0.005). Of particular note, eight of nine patients (89%) with a CD31-125LV heterozygous and CD31-563S/670R donor had acute GvHD, although overall the higher incidence of acute GvHD correlated strongly with the presence or absence of donor CD31-125LV heterozygosity.
As a result of the substantial effect of acute GvHD grade III and grade IV on patient survival, we considered the association between no or mild acute GvHD (grades 0 and I), moderate acute GvHD (grade II) and severe acute GvHD (grades III and IV) with donor CD31-125 genotype (Table 5 ). There is no difference between the incidence of moderate and severe GvHD (grades II, III and IV) and donor CD31-125 genotype, but these differed significantly compared to no or mild acute GvHD (P ¼ 0.01 and 0.03, respectively). The higher incidence of severe acute GvHD associated with donor CD31-125LV heterozygous genotype also influenced patient survival, with 67% survival at 1 year compared to 83% survival at 1 year with a CD31-125L or CD31-125V homozygous donor. This effect of donor CD31-125 genotype on patient survival was similar in both transplant centres independently, although the difference was not statistically significant.
Of the 85 cases studied, 66 patients survived beyond 100 days and were at risk of chronic GvHD. Our study identified a correlation between CD31-125LV donor heterozygosity and an increased incidence of chronic GvHD (P ¼ 0.06), although this is likely to be secondary to the strong link between acute and chronic GvHD (P ¼ 0.004, data not shown).
Discussion
GvHD following HLA-identical HST is initiated by immune responses towards polymorphic mHAg proteins located outside the major histocompatibility complex. We have analysed the distribution of CD31 genetic polymorphisms among recipients of HLA-identical stem cells and their donors. We report a strong correlation between donor CD31 genotype and the incidence and severity of acute GvHD, which was 2.5 times greater (59%) in haematopoietic stem cell recipients of a CD31-125LV heterozygous donor compared to a CD31-125L or 125V homozygous donor (23%, P ¼ 0.0019). Furthermore, this correlation was significant in both the Cambridge (P ¼ 0.019) and Manchester (P ¼ 0.015) patient cohorts independently, which strengthens the observation. Previous studies have produced contradictory reports concerning the role of CD31-125 and/or CD31-563/670 polymorphism and acute GvHD following HST. [2] [3] [4] [5] [6] [7] Behar et al suggested that donor and recipient CD31-125 nonidentity was a risk factor for acute GvHD grades II-IV, whereas Nichols et al found no influence of CD31 compatibility on acute GvHD. Furthermore, Maruya et al, Grumet et al and Balduini et al each reported that nonidentity or incompatibility for CD31-563/670 was a risk factor for acute GvHD and survival. These reports have focused on donor and recipient compatibility or identity, considering their role as a mHAg, but provide little information about the rate of acute GvHD as a function of donor CD31 genotype. Although we found a weak correlation between donor and recipient CD31-125 compatibility (in agreement with the above studies), closer scrutiny of our results suggest that this was, in fact, a function of donor genotype, where donor CD31-125LV heterozygosity accounted for the increased risk of acute GvHD.
There are several factors that may account for different findings between our study and that of others. Factors that can affect occurrence and severity of HST complication include age, gender, CMV status, disease type, conditioning regimen, stem cell source and dose. 11 In our patient population, only the nature of the original disease was related to the incidence of acute GvHD (P ¼ 0.078). However, there was no significant relationship between disease diagnosis and donor or recipient CD31-125 genotype (P ¼ 0.61 and 0.56, respectively). In addition, variation in study design such as inclusion of acute GvHD grade II, diagnostic ambiguity in the grading of acute GvHD and method of data analysis (recipient or donor genotype vs compatibility or identity) may account for discordant findings. Despite these differences our study adds to an increasing body of evidence that indicates an important role of CD31 gene polymorphism in HST.
The number of cases in our study is relatively small and therefore, our findings require confirmation. However, a recent study by Cavanagh et al 12 of 75 HLA identical sibling allogeneic bone marrow transplants from a single centre also reported worse overall survival associated with donor CD31 codon-125 heterozygosity (P ¼ 0.014). Taken together, these data support the suggestion that donor CD31 polymorphism may be important in determining HST outcome.
The mechanism underlying the association between donor CD31 genotype and GvHD is unclear. The composition of residue-125 or other closely linked polymorphism's in CD31 proteins may directly influence the function of leukocytes derived from transplanted stem cells. CD31-mediated adhesion plays a central role in the transmigration of lymphocytes across the vascular endothelium during an inflammatory response.
8 CD31 amino-acid residue 125 has an extra-cellular position between domains 1 and 2, a region that is likely to participate in cell-cell adhesion and may also be involved in signal transduction. 13 Recent studies have revealed that CD31 is expressed at the cell surface in monomeric, dimeric and oligomeric forms.
14 Dimers support cell-cell adhesion while CD31 oligomers are involved in signalling processes. Leukocytes derived from stem cells that are heterozygous at codon-125 will express both forms of CD31. It is plausible that the structure of these 'mixed' dimeric and oligomeric forms may influence cell adhesion or intracellular signalling, thus influencing leukocyte function.
The results of this study add further support towards a role of CD31 donor genotype in the pathogenesis of GvHD following haematopoietic stem cell transplantation. Similar studies using larger patient cohorts and investigation into the functional effect of CD31 genotype are therefore indicated. Acute GvHD grade 0-I vs II and donor CD31-125 genotype P ¼ 0.01. Acute GvHD grade 0-I vs III and IV donor CD31-125 genotype P ¼ 0.03.
